Zurück zur Übersicht
| Open forum infectious diseases. 2022 Jan 19. doi: 10.1093/ofid/ofac029. pii: ofac029. pmc: PMC8860165 |
| Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting. |
| Greenberg L1, Ryom L2, Neesgaard B3, Miró JM4, Dahlerup Rasmussen L5, Zangerle R6, Grabmeier-Pfistershammer K7, Günthard HF8, Kusejko K9, Smith C10, Mussini C11, Menozzi M12, Wit F13, Van Der Valk M14, d'Arminio Monforte A15, De Wit S16, Necsoi C17, Pelchen-Matthews A18, Lundgren J19, Peters L20, Castagna A21, Muccini C22, Vehreschild JJ23, Pradier C24, Bruguera Riera A25, Sönnerborg A26, Petoumenos K27, Garges H28, Rogatto F29, Dedes N30, Bansi-Matharu L31, Mocroft A32 |
 Collaborators
|
|
Author information
|
|
Abstract BACKGROUND: Limited data exist examining the association between incident cancer and cumulative integrase inhibitor (INSTI) exposure. METHODS: Participants were followed from baseline (latest of local cohort enrollment or January 1, 2012) until the earliest of first cancer, final follow-up, or December 31, 2019. Negative binomial regression was used to assess associations between cancer incidence and time-updated cumulative INSTI exposure, lagged by 6 months. RESULTS: Of 29 340 individuals, 74% were male, 24% were antiretroviral treatment (ART)-naive, and median baseline age was 44 years (interquartile range [IQR], 36-51). Overall, 13 950 (48%) individuals started an INSTI during follow-up. During 160 657 person-years of follow-up ([PYFU] median 6.2; IQR, 3.9-7.5), there were 1078 cancers (incidence rate [IR] 6.7/1000 PYFU; 95% confidence interval [CI], 6.3-7.1). The commonest cancers were non-Hodgkin lymphoma (n = 113), lung cancer (112), Kaposi's sarcoma (106), and anal cancer (103). After adjusting for potential confounders, there was no association between cancer risk and INSTI exposure (≤6 months vs no exposure IR ratio: 1.15 [95% CI, 0.89-1.49], >6-12 months; 0.97 [95% CI, 0.71-1.32], >12-24 months; 0.84 [95% CI, 0.64-1.11], >24-36 months; 1.10 [95% CI, 0.82-1.47], >36 months; 0.90 [95% CI, 0.65-1.26] [ = .60]). In ART-naive participants, cancer incidence decreased with increasing INSTI exposure, mainly driven by a decreasing incidence of acquired immune deficiency syndrome cancers; however, there was no association between INSTI exposure and cancer for those ART-experienced (interaction < .0001). CONCLUSIONS: Cancer incidence in each INSTI exposure group was similar, despite relatively wide CIs, providing reassuring early findings that increasing INSTI exposure is unlikely to be associated with an increased cancer risk, although longer follow-up is needed to confirm this finding. |
|
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |
|
KEYWORDS: HIV, antiretroviral treatment, cancer, cohort, integrase inhibitors |
|
Publikations ID: 35198646 Quelle: öffnen |
Collaborators
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
